COPD treatment

Top factors that predict 30-day COPD readmissionsRecent study findings reveal which patients are more likely to be readmitted for COPD problems, and which readmission reduction strategies might work best.
Long-term safety of glycopyrrolate: A randomized study of COPD patientsGlycopyrrolate bromide is a quick-onset long-acting muscarinic antagonist bronchodilator with FDA approval for use as maintenance treatment of COPD. Seebri Neohaler is approved for use at a dose of 15.6 ug inhaled twice daily.
Benzodiazepine use in older COPD patients may not be idealBenzodiazepine use in COPD patients linked to increased exacerbation, according to study out of Canada.
Health apps beneficial to help prevent COPD exacerbationA new report indicates the successes of early interventions through digital health applications to help manage COPD.
Smoke-free rules can help shield kids from COPDResearchers encourage smoke-free rules in homes, private cars, and outdoor children's play areas to help prevent and reduce long-term burden of COPD
Physical activity decreases over time in COPD patientsA new study finds that patients with COPD experience a decrease in physical activity over time, leading to further physical decline.
Large-scale COPD patient network in the worksA large chronic obstructive pulmonary disease (COPD) patient network is in the works.
Investigational dual bronchodilator improves lung function over single bronchodilators in COPDIn patients with moderate-to-severe chronic obstructive pulmonary disease (COPD), investigational indacaterol/glycopyrronium (QVA149) bromide significantly improved lung function compared to the single bronchodilators, according to data presented at the American Thoracic Society (ATS) International Conference in Denver, May 15 to 20.
[BLOG]: Best Practices between formulary managers and pharmacists to address challenges in COPD readmissionsTo address the burden of COPD on hospital expenditures, on October 1, 2014, the Centers for Medicare & Medicaid Services included COPD in its Hospital Readmissions Reductions Program. This inclusion resulted in reduced Medicare reimbursement for hospitals that demonstrate excessive 30-day COPD patient readmission rates.
FDA approves Striverdi Respimat to treat COPDFDA has approved olodaterol (Striverdi Respimat, Boehringer Ingelheim) Inhalation Spray 5 µg as a long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.